Prescription medicine
Glipizide Brand names: Glucotrol
Glipizide (Glucotrol) is a prescription medicine with an FDA approval on record since 1984. FDA's NDC Directory lists it from 31 generic labelers, and pharmacies paid $0.0339 per glipizide 5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the glipizide FDA label on DailyMed (effective January 8, 2026, Aurobindo Pharma Limited); the NDA 17783 record on Drugs@FDA; every glipizide label on DailyMed.
Highlights of the record
FDA label of January 8, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageGlipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Forms and strengths
- 2.5 mg
- 5 mg
- 10 mg
- 15 mg
Tablet; extended-release tablet; film-coated extended-release tablet.
On the market
- Earliest approval on file
- May 8, 1984 Glucotrol, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 21 first May 10, 1994; 12 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 32 of which 31 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.0339 per tablet Glipizide 5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 9 since 2016 0 Class I among all firms' recalls; latest December 17, 2024
- FAERS reports
- 60,555 through July 30, 2026
What is glipizide used for?
From the label: indications and usageGlipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Glipizide extended-release tablets is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Conditions named in the indications of glipizide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Sulfonylurea.
Source: FDA drug label (Glipizide), Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
What does the patient leaflet for glipizide say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking glipizide extended-release tablets?Do not drink alcohol while taking glipizide extended-release tablets. It can increase your chances of getting serious side effects. Do not drive, operate machinery, or do other dangerous activities until you know how glipizide extended-release tablets affect you.
Source: FDA drug label (Glipizide), Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
Is there a generic for glipizide (Glucotrol)?
The FDA approved the first generic glipizide on May 10, 1994. 21 generic applications are approved; 12 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists glipizide from 31 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1984 earliest approval on file
- 1994 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for glipizide (Glucotrol)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.0339 per Glipizide 5 mg tablet, down 2% from $0.0347 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Glipizide 5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Glipizide 10 mg tablet | Generic | $0.0448 per tablet | $1.34 | -2% |
| Glipizide 2.5 mg tablet | Generic | $1.27 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $38.02 | -0.1% |
| Glipizide 5 mg tablet | Generic | $0.0339 per tablet | $1.02 | -2% |
| Glipizide ER 10 mg tablet | Generic | $0.122 per tablet | $3.65 | -14% |
| Glipizide ER 2.5 mg tablet | Generic | $0.0993 per tablet | $2.98 | -9% |
| Glipizide ER 5 mg tablet | Generic | $0.0737 per tablet | $2.21 | -12% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has glipizide been recalled?
The FDA's Enforcement Report lists 9 recalls naming glipizide since 2016: 0 Class I (the most serious), 8 Class II, 1 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 17, 2024 | Class II | Amerisource Health Services LLC | Failed Dissolution Specifications: |
| September 17, 2021 | Class II | American Health Packaging | Failed Dissolution Specifications: results were above specification. |
| April 8, 2019 | Class II | American Health Packaging | Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero. |
| August 2, 2017 | Class III | Teva Pharmaceuticals USA | Failed Moisture Limits: out of specification test results for water content obtained during stability testing. |
| February 7, 2017 | Class II | RemedyRepack Inc. | Failed Dissolution Specifications |
| February 3, 2017 | Class II | Amerisource Health Services | Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point. |
| January 30, 2017 | Class II | Actavis Inc | Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point. |
| January 19, 2017 | Class II | Mylan Pharmaceuticals Inc. | Presence of Foreign Tablets/Capsules; bottles of Glipizide 5 mg tablets may contain Glipizide 10 mg tablets |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the glipizide label say about other medicines?
The glipizide label names 23 other medicines in its interaction, contraindication or warning sections. The labels of 11 other medicines name glipizide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. |
| Chloramphenicol | drug interactions | … salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. |
| Clonidine | drug interactions | Alcohol, beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of the glucose-lowering effect. |
| Clozapine | drug interactions | The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives … |
| Colesevelam | drug interactions | Glipizide extended-release tablets should be administered at least 4 hours prior to colesevelam ( 7.4 , 12.3 ). |
| Danazol | drug interactions | The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives … |
| Disopyramide | drug interactions | … and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal … |
| Epinephrine | drug interactions | … (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. |
| Fluconazole | drug interactions | An increase in glipizide AUC was seen after fluconazole administration ( 7.3 , 12.3 ). |
| Fluoxetine | drug interactions | … hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents … |
| Glucagon | drug interactions | The following are examples of medication that may reduce the glucose-lowering effect of glipizide extended-release tablets, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives … |
| Isoniazid | drug interactions | … antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid … |
| Miconazole | drug interactions | Severe hypoglycemia can occur when glipizide and oral miconazole are used concomitantly ( 7.2 , 12.3 ). Monitor patients closely. |
| Niacin | drug interactions | … antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid … |
Every other medicine the glipizide label names
| Medicine named | Section | What the label says |
|---|---|---|
| Octreotide | drug interactions | … pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole … |
| Olanzapine | drug interactions | … leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives … |
| Pentoxifylline | drug interactions | … disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics … |
| Phenytoin | drug interactions | … agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. |
| Pramlintide | drug interactions | … fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal … |
| Probenecid | drug interactions | … antibiotics, nonsteroidal anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. |
| Somatropin | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and … |
| Terbutaline | drug interactions | … somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. |
| Voriconazole | drug interactions | … anti-inflammatory agents, chloramphenicol, probenecid, coumarins, voriconazole, H2 receptor antagonists, and quinolones. |
Other labels that name glipizide
Source: FDA drug label (Glipizide), Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
What do FAERS reports show for glipizide?
The FDA Adverse Event Reporting System holds 60,555 reports that list glipizide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 5,339 are coded as a death and 18,120 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as glipizide?
32 other medicines are given the same way (oral) and in the same FDA class as glipizide or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Glimepiride | Type 2 diabetes | 29 labelers | $0.0507 per tablet 4 mg tablet | No current entry |
| Glyburide | Type 2 diabetes | 16 labelers | $0.0643 per tablet 5 mg tablet | A presentation being discontinued |
| Glyburide and metformin | Type 2 diabetes | 11 labelers | $0.171 per unit 2.5-500 mg | No current entry |
| Glimepiride and pioglitazone | Type 2 diabetes | none listed | $10.52 per unit 30-4 | No current entry |
| Metformin | Type 2 diabetes | 83 labelers | $0.0145 per tablet 500 mg tablet | No current entry |
| Pioglitazone | Type 2 diabetes | 22 labelers | $0.0675 per tablet 15 mg tablet | No current entry |
| Dapagliflozin and metformin | Type 2 diabetes | 8 labelers | $0.720 per tablet 10-1,000 mg tablet | No current entry |
| Metformin and sitagliptin | Type 2 diabetes | 4 labelers | $1.76 per tablet 50 mg-1,000 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does glipizide compare with medicines for the same use?
7 side-by-side pages set glipizide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to glipizide
- 32 medicines for the same use
- Other sulfonylureas
- the pharmacologic class, with prices and generics
- Glipizide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other